Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Curaxin CBL0100 Blocks HIV-1 Replication and Reactivation through Inhibition of Viral Transcriptional Elongation.

Jean MJ, Hayashi T, Huang H, Brennan J, Simpson S, Purmal A, Gurova K, Keefer MC, Kobie JJ, Santoso NG, Zhu J.

Front Microbiol. 2017 Oct 17;8:2007. doi: 10.3389/fmicb.2017.02007. eCollection 2017.

2.

Curaxin CBL0137 has the potential to reverse HIV-1 latency.

Jean MJ, Zhou D, Fiches G, Kong W, Huang H, Purmal A, Gurova K, Santoso NG, Zhu J.

J Med Virol. 2019 Aug;91(8):1571-1576. doi: 10.1002/jmv.25487. Epub 2019 May 1.

PMID:
30989696
3.

Screening of an FDA-approved compound library identifies levosimendan as a novel anti-HIV-1 agent that inhibits viral transcription.

Hayashi T, Jean M, Huang H, Simpson S, Santoso NG, Zhu J.

Antiviral Res. 2017 Oct;146:76-85. doi: 10.1016/j.antiviral.2017.08.013. Epub 2017 Aug 24.

4.

Current Strategies for Elimination of HIV-1 Latent Reservoirs Using Chemical Compounds Targeting Host and Viral Factors.

Jean MJ, Fiches G, Hayashi T, Zhu J.

AIDS Res Hum Retroviruses. 2019 Jan;35(1):1-24. doi: 10.1089/AID.2018.0153. Epub 2018 Dec 12.

5.

HIV "shock and kill" therapy: In need of revision.

Abner E, Jordan A.

Antiviral Res. 2019 Jun;166:19-34. doi: 10.1016/j.antiviral.2019.03.008. Epub 2019 Mar 23. Review.

PMID:
30914265
6.

Diversity of small molecule HIV-1 latency reversing agents identified in low- and high-throughput small molecule screens.

Hashemi P, Sadowski I.

Med Res Rev. 2019 Oct 13. doi: 10.1002/med.21638. [Epub ahead of print] Review.

PMID:
31608481
8.

FACT Proteins, SUPT16H and SSRP1, Are Transcriptional Suppressors of HIV-1 and HTLV-1 That Facilitate Viral Latency.

Huang H, Santoso N, Power D, Simpson S, Dieringer M, Miao H, Gurova K, Giam CZ, Elledge SJ, Zhu J.

J Biol Chem. 2015 Nov 6;290(45):27297-310. doi: 10.1074/jbc.M115.652339. Epub 2015 Sep 16.

9.

Finding a cure for HIV: will it ever be achievable?

Lewin SR, Evans VA, Elliott JH, Spire B, Chomont N.

J Int AIDS Soc. 2011 Jan 24;14:4. doi: 10.1186/1758-2652-14-4.

10.

Heat Shock Protein 90 Facilitates Latent HIV Reactivation through Maintaining the Function of Positive Transcriptional Elongation Factor b (p-TEFb) under Proteasome Inhibition.

Pan XY, Zhao W, Wang CY, Lin J, Zeng XY, Ren RX, Wang K, Xun TR, Shai Y, Liu SW.

J Biol Chem. 2016 Dec 9;291(50):26177-26187. Epub 2016 Oct 31.

11.

A new model for post-integration latency in macroglial cells to study HIV-1 reservoirs of the brain.

Schneider M, Tigges B, Meggendorfer M, Helfer M, Ziegenhain C, Brack-Werner R.

AIDS. 2015 Jun 19;29(10):1147-59. doi: 10.1097/QAD.0000000000000691.

PMID:
26035317
12.

A Novel Bromodomain Inhibitor Reverses HIV-1 Latency through Specific Binding with BRD4 to Promote Tat and P-TEFb Association.

Huang H, Liu S, Jean M, Simpson S, Huang H, Merkley M, Hayashi T, Kong W, Rodríguez-Sánchez I, Zhang X, Yosief HO, Miao H, Que J, Kobie JJ, Bradner J, Santoso NG, Zhang W, Zhu J.

Front Microbiol. 2017 Jun 7;8:1035. doi: 10.3389/fmicb.2017.01035. eCollection 2017.

13.

A novel bromodomain inhibitor, CPI-203, serves as an HIV-1 latency-reversing agent by activating positive transcription elongation factor b.

Liang T, Zhang X, Lai F, Lin J, Zhou C, Xu X, Tan X, Liu S, Li L.

Biochem Pharmacol. 2019 Jun;164:237-251. doi: 10.1016/j.bcp.2019.04.005. Epub 2019 Apr 13.

PMID:
30991051
14.

An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression.

Darcis G, Kula A, Bouchat S, Fujinaga K, Corazza F, Ait-Ammar A, Delacourt N, Melard A, Kabeya K, Vanhulle C, Van Driessche B, Gatot JS, Cherrier T, Pianowski LF, Gama L, Schwartz C, Vila J, Burny A, Clumeck N, Moutschen M, De Wit S, Peterlin BM, Rouzioux C, Rohr O, Van Lint C.

PLoS Pathog. 2015 Jul 30;11(7):e1005063. doi: 10.1371/journal.ppat.1005063. eCollection 2015 Jul.

15.

The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation.

Li Z, Guo J, Wu Y, Zhou Q.

Nucleic Acids Res. 2013 Jan 7;41(1):277-87. doi: 10.1093/nar/gks976. Epub 2012 Oct 18.

16.

Relationship between Measures of HIV Reactivation and Decline of the Latent Reservoir under Latency-Reversing Agents.

Petravic J, Rasmussen TA, Lewin SR, Kent SJ, Davenport MP.

J Virol. 2017 Apr 13;91(9). pii: e02092-16. doi: 10.1128/JVI.02092-16. Print 2017 May 1.

17.

Challenges and Opportunities for T-Cell-Mediated Strategies to Eliminate HIV Reservoirs.

Brockman MA, Jones RB, Brumme ZL.

Front Immunol. 2015 Oct 2;6:506. doi: 10.3389/fimmu.2015.00506. eCollection 2015. Review.

18.

Procyanidin trimer C1 derived from Theobroma cacao reactivates latent human immunodeficiency virus type 1 provirus.

Hori T, Barnor J, Nguyen Huu T, Morinaga O, Hamano A, Ndzinu J, Frimpong A, Minta-Asare K, Amoa-Bosompem M, Brandful J, Odoom J, Bonney J, Tuffour I, Owusu BA, Ofosuhene M, Atchoglo P, Sakyiamah M, Adegle R, Appiah-Opong R, Ampofo W, Koram K, Nyarko A, Okine L, Edoh D, Appiah A, Uto T, Yoshinaka Y, Uota S, Shoyama Y, Yamaoka S.

Biochem Biophys Res Commun. 2015 Apr 3;459(2):288-293. doi: 10.1016/j.bbrc.2015.02.102. Epub 2015 Feb 26. Erratum in: Biochem Biophys Res Commun. 2015 Jun 12;461(4):702.

PMID:
25727021
19.

Compounds producing an effective combinatorial regimen for disruption of HIV-1 latency.

Hashemi P, Barreto K, Bernhard W, Lomness A, Honson N, Pfeifer TA, Harrigan PR, Sadowski I.

EMBO Mol Med. 2018 Feb;10(2):160-174. doi: 10.15252/emmm.201708193.

20.

Estimating Initial Viral Levels during Simian Immunodeficiency Virus/Human Immunodeficiency Virus Reactivation from Latency.

Pinkevych M, Fennessey CM, Cromer D, Tolstrup M, Søgaard OS, Rasmussen TA, Keele BF, Davenport MP.

J Virol. 2018 Jan 2;92(2). pii: e01667-17. doi: 10.1128/JVI.01667-17. Print 2018 Jan 15.

Supplemental Content

Support Center